KNOWLEDGE BANK

Interviews

How can bioprinting enable better drug discovery?

CEO, Axolotl Biosciences
Dr Stephanie Willerth is a biomedical engineer entrepreneur and thought leader in D bioprinting and neural tissue engineering As CEO of Axolotl Biosciences and a Full Professor at the University of Victoria she leads innovations in personalized medicine through bioink development and human tissue models Her work bridges academia and industry bringing groundbreaking research into realworld healthca...

Articles

Futuristic Application of Human-On-A-Chip Technology

The drug development process is highly complex timeconsuming costly and labour intensive There are many steps involved in developing the novel therapeutics including target discovery and validation lead compound identification and optimisation preclinical studies clinical trials and finally the FDA review and approval Even after the development and approval of novel

Research Insights

Antitubercular Drugs For An Old Target: GSK693 As A Promising InhA Direct Inhibitor

Abstract Despite being one of the first antitubercular agents identified isoniazid INH is still the most prescribed drug for prophylaxis and tuberculosis TB treatment and together with rifampicin the pillars of current chemotherapy A high percentage of isoniazid resistance is linked to mutations in the prodrug activating enzyme KatG so the discovery of di

Case Studies

Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study

Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime

Techno Trends

Novel Retevmo® (selpercatinib) Developed for Advanced or Metastatic Solid Tumors

Eli Lilly and Company developed novel Retevmo selpercatinib mg mg capsules for the treatment of Advanced or Metastatic Solid Tumors in adults Retevmo is the novel and only approved RET inhibitor to receive both tumoragnostic accelerated approval and traditional approval in NSCLC thus providing meaningful clinical

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Quercetin - A Super Food For Therapeutic Interventions

Mohini Sikarwar

Mohini Sikarwar is a PhD Scholar at Centre for Development of Biomaterials, Sharda University, Greater Noida, India. Her research is focusing on advanced drug delivery systems with a commitment to enhancing therapeutic efficacy of poorly water-soluble drug for Leishmaniasis treatment. She is aiming to revolutionise the current treatment methods of Kala azar using drug delivery approaches.

 

Piyush Kumar Gupta

Dr. Piyush Kumar Gupta is currently head of the Centre for Development of Biomaterials at Sharda University, Greater Noida, India. His area of expertise belongs to Biomaterials, Pharmaceutics, and Nanotoxicology. He has published 143 SCIE and Scopus-indexed peer-reviewed articles and 7 book chapters in his area of expertise. He has been bestowed with several International or National awards.

 

2

Magnetic Nanoparticles and their Application Studies on Synthesis Characterisation

Prabhanjan S Giram

Prabhanjan S Giram qualified CSIR-NET AIR-81 in chemical sciences and received his Ph. D from National chemical laboratory, Pune. He Received Eudragit® 2018 Award of 1500 Euros from Evonik health care Germany. He also received newton Bhabha Fellowship from British council, UK and DBT, India. He has expertise in synthesis of biocompatible, biodegradable polymer with rationalised design of nanoformulation, nanofiber, semisolid dosage form such as ointment, creams, and gel.

 

Shubham R Musale

Shubham R Musale has graduate in pharmacy from Savitribai Phule Pune University. He got fellowship for M.pharm from AICTE. The Thesis titled for M.pharm Design of In-expensive Collector for preparation Electrospun Nanofiber. He has 2 review publication and 1 Book Chapter.

 

Sushil Y Raut

Sushil Y Raut has over 12 years of teaching and research experience. He has more than 25 research and review publications. He filed 3 Indian patents and over 20 national as well as international presentations in his credits. He is recipient of international research mobility fellowship and other prestigious awards.

 

3

Innovative Tool For Drug Design And Development

Subash Senthil

S.Subash awarded 2 best poster presentation awards and secured 1st place in Poster presentation. I published three articles in national and international peer reviewed journal. And, also attend many conferences to upgrade knowledge.

 

4

Endocrine Disrupting Compounds (EDCs)

Sintu Kumar Samanta

Sintu Kumar Samanta has been working as an Assistant professor in IIIT Allahabad, India. He did Ph.D. and post-doctoral research from IIT Kharagpur and IISc Bangalore, India respectively. He is working in the area of Biochemistry and Nanobiotechnology. He published research work in several international journals and filed one Indian patent.

 

 
Pavan Kumar Gautam

Pavan Kumar Gautamis presently working as a Post-Doctoral Fellow in the Department of Applied Sciences at IIIT Allahabad, India. He obtained Ph.D. from the University of Allahabad, India. His area of research is synthesis of nanoparticles for water remediation. He published his research work in many international journals.

 

5

Advanced Drug Delivery Systems for Chronic Liver Disease Management

Jyothi U. Menon

Jyothi U Menon received her PhD in Biomedical Engineering from the University of Texas (UT) Arlington and UT Southwestern Medical Center joint program. She completed her postdoctoral training at the University of Oxford, UK. She is currently an Associate Professor in the College of Pharmacy at the University of Rhode Island where her research focus is on targeted drug delivery systems to treat lung and liver diseases, and in vitro disease modeling.

 

press releasesRead more...

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

Monod Bio a Seattlebased AIenabled protein design company and SignalChem Biotech Inc a whollyowned subsidiary of Sino Biological Inc SZSE today announced a nonexclusive licensing agreement

Lotus Pharmaceutical Announces Favorable U.S. Appeals Court Ruling on Norwich’s Application for Generic Rifaximin

Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange a leading global pharmaceutical company today announced that Norwich Pharmaceuticals Inc Norwich a wholly owned subsidiary of Alvogen

SK Biopharmaceuticals to In-License Epilepsy Drug Candidate ‘Opakalim’ Paves the Way to Launch its Second Innovative Drug Directly in the U.S.

SK Biopharmaceuticals Co Ltd wwwskbpcom CEO Donghoon Lee held a press conference on August th and announced that it has entered into an agreement to inlicense opakalim an investigational

DKSH Performance Materials Expands its Pharma Business Through the Acquisition of P.R. Chemicals in Thailand

DKSH has signed an agreement to acquire PR Chemicals Company Limited PR Chemicals a Thai distributor specialized in Active Pharmaceutical Ingredients APIs

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Celltrion KRX today announced the launch of the mg strength of Omlyclo omalizumab a treatment for chronic spontaneous urticaria and allergic asthma in Europe With the addition

ASTRI and Saint Francis University Sign MoU to Advance AI-Enabled Biomaterials and Digital Health Innovation

The Hong Kong Applied Science and Technology Research Institute ASTRI and Saint Francis University SFU have signed a Memorandum of Understanding MoU to establish a strategic partnership focused on advancing

EventsRead more...

03 - 05

Sep 2026

5th MENA Congress for Rare Diseases 2026

Beach Rotana Hotel, Abu Dhabi,...

14 - 15

Sep 2026

16th American DDF Summit

Omni Boston Hotel at the Seapo...

15 - 17

Sep 2026

COPD Drug Development Summit 2026

Street, Boston, MA 02210, USA

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

28 - 01

Sep 2026

LATEST NEWSRead more...

Jazz Pharmaceuticals Announces Approval of Ziihera Regimens for Advanced HER2-Positive Gastroesophageal Cancer

Jazz Pharmaceuticals has announced that the US Food and Drug Administration FDA has approved two Ziihera zanidatamabhriibased treatment regimens for the firstline treatment of adults with unresectable

BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients

BioCryst Pharmaceuticals has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORLADEYO berotralstat for the prevention of hereditary angioedema HAE attacks in children aged to under years

Takeda Receives Approval for ORZEYFUL (oveporexton) to Treat Narcolepsy Type 1

Takeda has announced that Japans Ministry of Health Labour and Welfare MHLW has approved ORZEYFUL oveporexton for the treatment of narcolepsy type NT a form of narcolepsy associated with cataplexy in adults

Johnson & Johnson’s IMAAVY Approved in the US as First Treatment for Warm Autoimmune Haemolytic Anaemia

Johnson Johnson has announced that the US Food and Drug Administration FDA has approved IMAAVY nipocalimabaahu for the treatment of warm autoimmune haemolytic anaemia wAIHA in adults and children aged years and older who are currently or previously treated with corticosteroids

Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan

Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange has received marketing approval in Japan for its generic pomalidomide capsules in mg mg mg and mg strengths following a review

Ultragenyx Receives U.S. FDA Approval for GENGLYCOS Gene Therapy for Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical Inc NASDAQ RARE has received accelerated approval from the US Food and Drug Administration FDA for GENGLYCOS pariglasgene brecaparvovecopnr also known as DTX for adults and children aged eight years and older with glycogen storage disease type Ia GSDIa